Peter H. O’Donnell
Impact in
Papers in
- Co-authors
- Noah M. Hahn (26 shared papers)Arjun Vasant Balar (26 shared papers)Joaquim Bellmunt (23 shared papers)Elizabeth R. Plimack (26 shared papers)M. Eileen Dolan (9 shared papers)Petros Grivas (26 shared papers)Rodolfo F. Perini (7 shared papers)Daniel Castellano (19 shared papers)
- Journals
- Journal of Clinical Oncology (56 papers)Annals of Oncology (14 papers)Cancer (7 papers)Pharmacogenetics and Genomics (6 papers)The Pharmacogenomics Journal (5 papers)
- Partner nations
- United StatesUnited KingdomSpain
In The Last Decade
Peter H. O’Donnell
158 papers receiving 6.3k citations
Peter H. O’Donnell's Hit Papers
Peers
Comparison fields: 5 of 107
- Oncology 2.8k
- Surgery 3.3k
- Pharmacology 467
- Immunology 735
- Pulmonary and Respiratory Medicine 748
Countries citing papers authored by Peter H. O’Donnell
This map shows the geographic impact of Peter H. O’Donnell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter H. O’Donnell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter H. O’Donnell more than expected).
Fields of papers citing papers by Peter H. O’Donnell
This network shows the impact of papers produced by Peter H. O’Donnell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter H. O’Donnell. The network helps show where Peter H. O’Donnell may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter H. O’Donnell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 170 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study Hit paper breakdown → | 2017 | 959 |
| 2 | Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Hit paper breakdown → | 2017 | 665 |
| 3 | Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer Hit paper breakdown → | 2016 | 663 |
| 4 | Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy Hit paper breakdown → | 2019 | 450 |
| 5 | Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study Hit paper breakdown → | 2017 | 261 |
| 6 | Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer Hit paper breakdown → | 2020 | 204 |
| 7 | 2009 | 194 | |
| 8 | Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial Hit paper breakdown → | 2021 | 189 |
| 9 | 2012 | 133 | |
| 10 | 2016 | 126 | |
| 11 | Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin Hit paper breakdown → | 2022 | 97 |
| 12 | 2014 | 92 | |
| 13 | 2015 | 90 | |
| 14 | 2022 | 69 | |
| 15 | 2015 | 66 | |
| 16 | 2014 | 65 | |
| 17 | 2009 | 64 | |
| 18 | 2017 | 61 | |
| 19 | 2017 | 58 | |
| 20 | 2017 | 49 |
About Peter H. O’Donnell
Peter H. O’Donnell is a scholar working on Surgery, Oncology, Pharmacology, Pulmonary and Respiratory Medicine and Molecular Biology, having authored 170 papers that have together received 6.4k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (88 papers), Cancer Immunotherapy and Biomarkers (48 papers), Pharmacogenetics and Drug Metabolism (33 papers), Urinary and Genital Oncology Studies (33 papers), Pharmaceutical studies and practices (12 papers), Esophageal Cancer Research and Treatment (10 papers), Prostate Cancer Treatment and Research (8 papers) and Cancer Treatment and Pharmacology (7 papers). The work is most often cited by research in Oncology (2.8k citations), Surgery (3.3k citations), Pharmacology (467 citations), Immunology (735 citations) and Pulmonary and Respiratory Medicine (748 citations). Peter H. O’Donnell has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Noah M. Hahn, Arjun Vasant Balar, Joaquim Bellmunt, Elizabeth R. Plimack, M. Eileen Dolan, Petros Grivas, Rodolfo F. Perini, Daniel Castellano, Thomas Powles and Ronald de Wit. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer, Pharmacogenetics and Genomics and The Pharmacogenomics Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.